Elizabeth Miller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3297697/publications.pdf

Version: 2024-02-01

36 papers	3,974 citations	257101 24 h-index	377514 34 g-index
38 all docs	38 docs citations	38 times ranked	3754 citing authors

#	Article	IF	Citations
1	Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infectious Diseases, The, 2011, 11, 760-768.	4.6	572
2	Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infectious Diseases, The, 2015, 15, 535-543.	4.6	474
3	Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infectious Diseases, The, 2014, 14, 839-846.	4.6	416
4	Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000â€“17: a prospective national observational cohort study. Lancet Infectious Diseases, The, 2018, 18, 441-451.	4.6	403
5	Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ, The, 2013, 346, f794-f794.	3.0	254
6	Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study. PLoS Medicine, 2011, 8, e1001017.	3.9	251
7	Antibody Responses to Nasopharyngeal Carriage ofStreptococcus pneumoniaein Adults: A Longitudinal Household Study. Journal of Infectious Diseases, 2005, 192, 387-393.	1.9	213
8	Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine, 2012, 30, 6802-6808.	1.7	190
9	Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. Lancet Infectious Diseases, The, 2022, 22, 603-610.	4.6	154
10	Immunogenicity and Boosting After a Reduced Number of Doses of a Pneumococcal Conjugate Vaccine in Infants and Toddlers. Pediatric Infectious Disease Journal, 2006, 25, 312-319.	1.1	141
11	Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1â€ˆ+â€ˆ1) compared with two primary doses and a booster (2â€ˆ+â€ˆ1) in UK infants: a multicentre, parallel group randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 171-179.	4.6	97
12	Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. PLoS ONE, 2018, 13, e0195799.	1.1	80
13	Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. BMC Medicine, 2018, 16, 13.	2.3	76
14	Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infectious Diseases, 2010, 10, 90.	1.3	73
15	The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. PLoS Medicine, 2015, 12, e1001839.	3.9	66
16	Using the Indirect Cohort Design to Estimate the Effectiveness of the Seven Valent Pneumococcal Conjugate Vaccine in England and Wales. PLoS ONE, 2011, 6, e28435.	1.1	56
17	7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement?. PLoS ONE, 2011, 6, e26190.	1.1	52
18	The Social Life of Infants in the Context of Infectious Disease Transmission; Social Contacts and Mixing Patterns of the Very Young. PLoS ONE, 2013, 8, e76180.	1.1	49

#	Article	IF	Citations
19	Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England. Sleep, 2016, 39, 1051-1057.	0.6	44
20	Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales. PLoS ONE, 2012, 7, e39927.	1.1	41
21	Inference of the SARS-CoV-2 generation time using UK household data. ELife, 2022, 11, .	2.8	40
22	Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. Journal of Infection, 2021, 83, 483-489.	1.7	37
23	Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study. PLoS Medicine, 2019, 16, e1002845.	3.9	34
24	The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination. Proceedings of the Royal Society B: Biological Sciences, 2013, 280, 20131939.	1.2	29
25	Influenza and RSV make a modest contribution to invasive pneumococcal disease incidence in the UK. Journal of Infection, 2013, 66, 512-520.	1.7	26
26	Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillainâ€“BarrÃ© Syndrome and Narcolepsy. CNS Drugs, 2020, 34, 1-8.	2.7	21
27	Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. Biologicals, 2019, 60, 1-7.	0.5	18
28	Invasive Pneumococcal Disease, Comorbidities, and Polysaccharide Vaccine Use in Children Aged 5-15 Years in England and Wales. Clinical Infectious Diseases, 2014, 58, 517-525.	2.9	17
29	Impact of COVID-19 social distancing measures on future incidence of invasive pneumococcal disease in England and Wales: a mathematical modelling study. BMJ Open, 2021, 11, e045380.	0.8	15
30	Pneumococcal pneumonia. Thorax, 2020, 75, 6-7.	2.7	7
31	Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America. Vaccine, 2021, 39, 1551-1555.	1.7	7
32	Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study. PLoS Medicine, 2020, 17, e1003225.	3.9	6
33	Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: An ecological study. Vaccine, 2020, 38, 4816-4819.	1.7	6
34	Rapid evaluation of the safety of COVID-19 vaccines: how well have we done?. Clinical Microbiology and Infection, 2022, 28, 477-478.	2.8	6
35	Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing. Vaccine, 2020, 38, 7834-7841.	1.7	0
36	Predicting the efficacy of new coronavirus vaccines â€“ Are neutralising antibodies enough?. EBioMedicine, 2022, 79, 104034.	2.7	0